Enlivex Therapeutics Ltd.
ENLV
$1.09
$0.1414.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 39.17% | -5.07% | -12.72% | 25.81% | -39.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.02% | 3.08% | -11.29% | -10.01% | -44.58% |
| Operating Income | 18.02% | -3.08% | 11.29% | 10.01% | 44.58% |
| Income Before Tax | 15.26% | 39.66% | 16.62% | 43.09% | 56.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.26% | 39.66% | 16.62% | 43.09% | 56.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.26% | 39.66% | 16.62% | 43.09% | 56.36% |
| EBIT | 18.02% | -3.08% | 11.29% | 10.01% | 44.58% |
| EBITDA | 16.29% | -5.91% | 9.25% | 7.57% | 45.36% |
| EPS Basic | 25.02% | 50.57% | 34.28% | 52.94% | 61.85% |
| Normalized Basic EPS | 25.00% | 50.61% | 31.56% | 24.66% | 61.88% |
| EPS Diluted | 25.02% | 50.00% | 32.16% | 52.94% | 61.85% |
| Normalized Diluted EPS | 25.00% | 50.61% | 31.56% | 24.66% | 61.88% |
| Average Basic Shares Outstanding | 13.01% | 22.05% | 26.87% | 20.93% | 14.41% |
| Average Diluted Shares Outstanding | 13.01% | 22.05% | 26.87% | 20.93% | 14.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |